CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6930 result(s)

Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Physical Activity

Event Date: September 23, 2020
Result type: Events

Because of the prevalence and burden of chronic pain, health care providers are in search of the best multifaceted approach for treatment knowing that relying on opioids alone can be ineffective and carries substantial risks. Join CADTH for a webinar on the current evidence on physical activity for chronic, non-cancer pain. The target audience f...

Blood Plasma Therapies For COVID-19

Event Date: August 25, 2020
Result type: Events

With the COVID-19 pandemic showing no signs of slowing down, there’s a lot of interest in the global effort to develop a vaccine. Below the radar, researchers are exploring many other treatment options, including a century-old therapy that has been used to combat outbreaks of polio, measles, mumps, and influenza. Convalescent plasma therapy, whi...

e-Consult for Primary Care Clinician Access to Specialists

Last Updated: August 13, 2020
Result type: Reports
Research Type: Device

E-Consult (also known as e-Consultation, electronic consultation, or remote consultation) is a type of asynchronous telehealth (also known as store-and-forward) that connects primary care providers with specialists. In an e-Consult service, primary care providers send a request for consultation through the system to a specialist, who then respon...

  • Project Number: HT0030-000

Levetiracetam (pdp-levETIRAcetam)

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Levetiracetam
Indications: Epilepsy

  • Brand Name: pdp-levETIRAcetam
  • Manufacturer: Pendopharm, a division of Pharmascience Inc.
  • Project Number: SR0653-000
  • Project Status: Active
  • Submission Type: New

nintedanib (Ofev)

Last Updated: August 11, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: nintedanib
Indications: chronic fibrosing interstitial lung diseases

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Received
  • Submission Type: New

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: August 10, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: von Willebrand Factor [recombinant]
Indications: von Willebrand disease, adults, treatment and perioperative management

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: New